Alfuzosin (CED0006529)

Record Information
Version1.0
Creation Date2016-05-25 18:19:47 UTC
Update Date2026-08-20 04:04:25 UTC
Accession NumberCHEM022092
Identification
Common NameAlfuzosin
ClassSmall Molecule
Description
Alfuzosin is an organic compound with the formula C19H27N5O4 and an average molecular weight of 389.45 g/mol. Alfuzosin belongs to the benzodiazines, a subclass of diazanaphthalenes within the organic compounds. This substance functions as an antagonist of three protein targets: the Alpha-1A adrenergic receptor (ADRA1A), the Alpha-1B adrenergic receptor (ADRA1B), and the Alpha-1D adrenergic receptor (ADRA1D). The compound is identified in six recorded sources across various categories. In the realm of healthcare, pharmaceuticals, and veterinary products, it is utilized as a drug for the treatment of benign prostatic hypertrophy. It is also found in household cleaning and consumer products, specifically within tobacco smoke filters, cigar cigarettes, and other smoking requisites. Additionally, it has been detected in indoor air as part of air, dust, and atmospheric transport, as well as in electrically stimulated smoking devices categorized under electrical and electronic equipment. Exposure to alfuzosin occurs through oral and inhalation routes.
Contaminant Type
  • Human Neurotoxin
Chemical Structure
Synonyms
ValueSource
AlfuzosinaChEBI
AlfuzosineChEBI
AlfuzosinumChEBI
XatralKegg
AlfusosineHMDB
N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamideHMDB
UroXatralHMDB
AlfusozineHMDB
UrionHMDB
Alfuzosin hydrochlorideHMDB
AlphuzosineHMDB
AlfetimHMDB
BenestanHMDB
Chemical FormulaC19H27N5O4
Average Molecular Mass389.449 g/mol
Monoisotopic Mass389.206 g/mol
CAS Registry Number81403-80-7
IUPAC NameN-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide
Traditional Namealfuzosin
SMILESCOC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1
InChI IdentifierInChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
InChI KeyWNMJYKCGWZFFKR-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazanaphthalenes
Sub ClassBenzodiazines
Direct ParentQuinazolinamines
Alternative Parents
Substituents
  • Quinazolinamine
  • Anisole
  • Dialkylarylamine
  • Alkyl aryl ether
  • Aminopyrimidine
  • Pyrimidine
  • Imidolactam
  • Benzenoid
  • Heteroaromatic compound
  • Tetrahydrofuran
  • Carboximidic acid
  • Carboximidic acid derivative
  • Dialkyl ether
  • Ether
  • Oxacycle
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Organonitrogen compound
  • Organooxygen compound
  • Hydrocarbon derivative
  • Organic nitrogen compound
  • Organic oxygen compound
  • Organopnictogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Biological Properties
StatusDetected and Not Quantified
OriginNot Available
Cellular LocationsNot Available
Biofluid LocationsNot Available
Tissue LocationsNot Available
ApplicationsNot Available
Biological RolesNot Available
Chemical RolesNot Available
Organoleptic EffectsNot Available
Physical Properties
StateNot Available
AppearanceNot Available
Experimental Properties
PropertyValue
Melting PointNot Available
Boiling PointNot Available
SolubilityNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.28 g/LALOGPS
logP2.02ALOGPS
logP1.19ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.64ChemAxon
pKa (Strongest Basic)7.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area111.83 ŲChemAxon
Rotatable Bond Count8ChemAxon
Refractivity107.11 m³·mol⁻¹ChemAxon
Polarizability42.71 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Spectra
Spectra
Spectrum TypeDescriptionSplash KeyDeposition DateView
Predicted GC-MSPredicted GC-MS Spectrumsplash10-00fr-9244000000-7f0f72006d4f335adfd0Not AvailableView Spectrum
Predicted GC-MSPredicted GC-MS SpectrumNot AvailableNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-000i-0009000000-b390e2d32ee38fb79cf9Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-00dr-0039000000-1058f618ea52b7aa95e6Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0aos-0195000000-97624e7dcce906c3a1eeNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0udi-0391000000-6d58b29a79c5af262723Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0udi-1970000000-b3cb9821b3584d86539fNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0i6s-1920000000-50ca3c071a5548796b3aNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-014i-5900000000-b3a86e227650a23790ecNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-014i-9400000000-9929aaf0359abea0c166Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-014i-9100000000-b3dba930d4cfe0d28a8eNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0006-0009000000-58fd75abdf178ea1b331Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0006-0119000000-90a7799e494035d224e7Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0abi-5791000000-648d5529faeac9e35dc0Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-00di-9260000000-591f2bacf7d82aeba7e3Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-00di-9250000000-d107a0e9675604325bb1Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-00di-9340000000-f708562f3998488d7fceNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-00di-7910000000-3fe44ce2a42f727569e2Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-05fr-8900000000-dca38c682ad0b6c90b46Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0bvl-9300000000-bad5c36d48e0e93a82aaNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0006-0249000000-93552ff8c72ff220f172Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0006-0009000000-58fd75abdf178ea1b331Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0udi-1970000000-b0fb2369c6ec0dac4da7Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-000i-0009000000-f7c6ce96d2befa6613a6Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-052o-1689000000-3d4056a0cfaf3a82ba03Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0udi-0391000000-32434b3553430d980c1eNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-00dr-0039000000-a58e0a0d76403628e0daNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0aos-0195000000-eb21ba4a837e918890c0Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-000i-0009000000-8dc8c9a659cbb0b66e31Not AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0abi-6791000000-5c785b2846ed0b62783eNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-0006-0119000000-d7c80f8ee62621b1e06eNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-00di-9250000000-46ac706972d35cb89d9bNot AvailableView Spectrum
LC-MS/MSLC-MS/MS Spectrumsplash10-00di-9140000000-1289af78e0fdbba367e5Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-0006-0092000000-4b7c2dae5894c14b8575Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-006x-1090000000-a62c896d99f7b9d73c0aNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-000i-3090000000-381d1c6c96f3e65c44e0Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-000i-1139000000-3af55917407f4facdb0bNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-00yi-4193000000-b8b9ec6006943f78ab01Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-017i-6390000000-a64c36b6d4e976a6272fNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-000i-0009000000-78a904a53701d2967cf4Not AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-000i-1029000000-4761f9cb56623d59d64fNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-0fs9-1195000000-27de18ebbd71d76a94ecNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-0006-0009000000-7b87d2f62830ce5f72afNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-0006-5097000000-18e8a37e6f5969418d4aNot AvailableView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrumsplash10-00sj-8192000000-582200abbe9e620dcad6Not AvailableView Spectrum
Toxicity Profile
Mechanism of ToxicityNot Available
Carcinogenicity (IARC Classification)Not Available
Minimum Risk LevelNot Available
SymptomsNot Available
TreatmentNot Available
Toxicity Values
Toxicity ValueUnitValue RangeOrganismDose DescriptorRoute of ExposurePredicted or ExperimentalReference
1312.0Log mg/kg[740:2300]RatLD50oralpredictedNot Available
Health Effects
Health EffectRelationshipDirectionReference
Exposure Sources
Source IDSourceSectorReference
10InsecticidesAgriculture & land managementNot Available
19Indoor airAir, dust & atmospheric transportNot Available
233BrushesPersonal care & cosmeticsNot Available
327Drugs used in benign prostatic hypertrophyHealthcare, pharmaceuticals & veterinary productsNot Available
518Electrically Stimulated Smoking DevicesElectrical & Electronic EquipmentNot Available
556Cigar CigarettesHousehold cleaning & consumer productsNot Available
560Other Smoking RequisitesHousehold cleaning & consumer productsNot Available
569Tobacco Smoke FiltersHousehold cleaning & consumer productsNot Available
580Manufacture Preparation Of Tobacco ProductsIndustrial manufacturing & chemical processingNot Available
610Aftersun ProductsPersonal care & cosmeticsNot Available
611Anti Perspirants Or Body DeoderantsPersonal care & cosmeticsNot Available
632ApparelTextiles, leather & furnishingsNot Available
Pathways
1 pathway
Targets
StructureProteinUniProt IDOrganismRelationshipDetails
Click to view 3D structureAlpha-1A adrenergic receptorP43140Rattus norvegicusPredicted (SEA)3.11397
Click to view 3D structureAlpha-1B adrenergic receptorP15823Rattus norvegicusPredicted (SEA)0.934191
Click to view 3D structureAlpha-1D adrenergic receptorP23944Rattus norvegicusPredicted (SEA)2.88042
Alpha-1A adrenergic receptor structureClick to view 3D structureAlpha-1A adrenergic receptorP35348HumansPredicted (SEA)9.73115
Click to view 3D structureAlpha-1D adrenergic receptorP25100HumansPredicted (SEA)4.20386
Click to view 3D structureAlpha-1B adrenergic receptorP35368HumansPredicted (SEA)6.15009
Click to view 3D structureAlpha-1A adrenergic receptorP18130Bos taurusPredicted (SEA)1.94623
Acetylcholinesterase structureClick to view 3D structureAcetylcholinesteraseP22303HumansPredicted (SEA)54.5723
Click to view 3D structureD(2) dopamine receptorP61169RatPredicted (SEA)139.039
Alpha-2C adrenergic receptor structureClick to view 3D structureAlpha-2C adrenergic receptorP18825HumansPredicted (SEA)82.5202
Alpha-2B adrenergic receptor structureClick to view 3D structureAlpha-2B adrenergic receptorP18089HumansPredicted (SEA)72.0884
5-hydroxytryptamine receptor 1A structureClick to view 3D structure5-hydroxytryptamine receptor 1AP08908HumansPredicted (SEA)291.623
Click to view 3D structure5-hydroxytryptamine receptor 1AP19327Rattus norvegicusPredicted (SEA)213.774
Alpha-2A adrenergic receptor structureClick to view 3D structureAlpha-2A adrenergic receptorP08913HumansPredicted (SEA)140.596
Click to view 3D structureAlpha-1B adrenergic receptorP18841Mesocricetus auratusPredicted (SEA)4.43741
Histone-lysine N-methyltransferase EHMT2 structureClick to view 3D structureHistone-lysine N-methyltransferase EHMT2Q96KQ7HumansPredicted (SEA)47.4102
Click to view 3D structure5-hydroxytryptamine receptor 2AP14842Rattus norvegicusPredicted (SEA)275.431
PHD finger protein 19 structureClick to view 3D structurePHD finger protein 19Q5T6S3HumansPredicted (SEA)11.9109
Click to view 3D structureBeta-caseinP02665Rattus norvegicusPredicted (SEA)1.86838
Histone-lysine N-methyltransferase EHMT1 structureClick to view 3D structureHistone-lysine N-methyltransferase EHMT1Q9H9B1HumansPredicted (SEA)22.732
Spindlin-3 structureClick to view 3D structureSpindlin-3Q5JUX0HumansPredicted (SEA)16.2705
Spindlin-2B structureClick to view 3D structureSpindlin-2BQ9BPZ2HumansPredicted (SEA)16.2705
Spindlin-4 structureClick to view 3D structureSpindlin-4Q56A73HumansPredicted (SEA)16.2705
Click to view 3D structureAlpha-1A adrenergic receptorO02824Oryctolagus cuniculusPredicted (SEA)28.415
Histone deacetylase 1 structureClick to view 3D structureHistone deacetylase 1Q13547HumansPredicted (SEA)898.38
Concentrations
Not Available
External Links
DrugBank IDDB00346
HMDB IDHMDB0014490
FooDB IDNot Available
Phenol Explorer IDNot Available
KNApSAcK IDNot Available
BiGG IDNot Available
BioCyc IDNot Available
METLIN IDNot Available
PDB IDNot Available
Wikipedia LinkAlfuzosin
Chemspider ID2008
ChEBI ID51141
PubChem Compound ID2092
Kegg Compound IDNot Available
YMDB IDNot Available
ECMDB IDNot Available
References
Synthesis ReferenceNot Available
MSDSNot Available
General References
1. Wilde MI, Fitton A, McTavish D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29.
2. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15.
3. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4.
4. McKeage K, Plosker GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
5. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96.